INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant drinking (alcohol) or other known history liver diseases. NAFLD resembles alcohol-induced fatty liver damage, which can develop into nonalcoholic steatohepatitis (NASH) and, eventually, hepatocellular carcinoma [1]. NAFLD is the most common cause of chronic liver disease worldwide. Approximately 20% to 30% of adults in developed countries suffer from NAFLD [2], and the prevalence of NAFLD in obese adults and those suffering from type 2 diabetes mellitus has increased to 75% and 50% to 75%, respectively [34]. NAFLD is a multifactorial disease [5]. Inflammatory, environmental, metabolic, and various genetic factors and diets (the most important factor) have been considered in its pathogenesis. Up to 80% of obese people suffer from NAFLD disease [67]. NAFLD is a new challenge in the field of modern medicine. There are two routes to relieve NAFLD: one route is inhibiting triglyceride (TG) synthesis, and the other one is promoting the metabolism of TGs. Hepatic steatosis can be improved by inhibiting lipid synthesis and promoting fatty acid oxidation, especially β-oxidation [2].

NAFLD is an acquired metabolic stress-induced liver injury associated with insulin resistance and genetic susceptibility [89]. Endogenous ethanol [10], gut microbiota [5], and hepatic tumor necrosis factor α (TNF-α) [11] play important roles in the pathogenesis of NAFLD. Systemic inflammation can be induced by high-fat diets (HFDs); insulin resistance, weight gain, and nonalcoholic fatty liver can be caused by disturbed metabolic homeostasis and gut microbial derangements. In patients with fatty liver, intestinal bacterial overgrowth is common [1213]. Intestinal permeability is associated with a fatty liver. The risk of spontaneous bacterial peritonitis can be increased by the increased intestinal permeability [14]. In addition, the bacterial endotoxin has been considered as a hepatotoxin [15], which is produced by gram-negative bacteria. Considerable evidence shows that the balance of gut microbiota and insulin resistance is considered a key role in the pathogenesis of NAFLD and NASH [516].

Fortunately, accumulating evidence has shown that probiotics are able to inhibit harmful bacteria and improve gastrointestinal barrier function [17]. In particular, various Lactobacilli isolates attenuated liver pathology via stabilization of the intestinal barrier and anti-inflammatory actions [18]. A study demonstrated that alanine transaminase (ALTase), aspartate transaminase (ASTase), TNF-α, and total cholesterol (TC) of NAFLD patients were reduced by Lactobacillus, Bifidobacterium, and Streptococcus [19]. Previous studies found that the serum lipid profiles can be influenced by Lactobacillus and Bifidobacterium [20].

Probiotics should impart the ability to tolerate gastric acidity and bile toxicity, survive under stressed conditions of the intestine and have antimicrobial effects against pathogens [21]. In this study, we attempt to relieve NAFLD by blocking TG synthesis (or enhancing TG metabolism) and reducing insulin resistance. The probiotics from the fecal microbiota of healthy adults were screened for cholesterol and TG clearance. Moreover, polysaccharides were also screened for insulin resistance improvement. We aim to quickly establish methods for probiotic screening, and the effect of a probiotic combination (Lactobacillus plantarum+Bifidobacterium bifidum+polysaccharide) on the mitigation of NAFLD was examined.

METHODS

Isolation of probiotics from fecal microbiota of healthy adults

Samples were collected from fecal microbiota in healthy adults. To ensure general health, the vital signs of volunteers were assessed and inclusion criteria were as follows: (1) 20 to 30 years of age; (2) free of known gastrointestinal and metabolic diseases, no history of gastrointestinal or metabolic disorders; (3) avoid taking medications; (4) limit alcohol consumption; (5) agree to avoid any changes in chronic medications; (6) willing to fill out all necessary research questionnaires and donate stool specimens; and (7) voluntary signing of written informed consent prior to participation in the study. Stool samples were harvested in sterile transparent-glass tubes (20 mL) and stored at 4℃. Stools were diluted by 10⁻⁴ to 10⁻⁶ with sterilized saline. Then, 50-µL dilutions were spread onto the MRS (de MAN, ROGOSA and SHARPE) broth, and MRSP (MRS broth was added with 1.8 mmol/L sodium thioglycolate, 2.8 mmol/L L-cysteine hydrochloride, and 0.9 mmol/L CaCl₂) and M₁₇ agar plates in anaerobic incubation at 37℃ for 48 hours.

Probiotics and polysaccharide screening

The cholesterol-lowering capability of the candidate strains determined by the ferric ammonium sulfate [2223]. Briefly, isolates were inoculated (1%, v/v) into MRSC broth (MRS broth supplemented with 1.0 g/L cholesterol) and incubated at 37℃ for 48 hours anaerobically. Next, 200-µL cultures were mixed with 4,800 µL ethanol after incubation. Then, the cells were removed by centrifugation (4,500 rpm, 20 minutes) at 4℃. Next, 4 mL of supernatant was slowly added to 2 mL of ferric ammonium sulfate reagent (Aladdin, Shanghai, China) and mixed well. The absorbance of the supernatant was measured by a spectrophotometer (Shimadzu, Kyoto, Japan) at 560 nm. The uninoculated samples were used as a negative control. Cholesterol clearance (CC) was calculated by the following formula: CC=[(A_o−A)/A_o]×100%, where A_o and A are the absorbance of uninoculated and inoculated samples, respectively.

The TG-reducing activity was tested according to the Saravanan and Ponmurugan [24] method. Isolates were inoculated (1%, v/v) into 25 mL of MRST broth (MRS broth supplemented with 1.0 g/L TG) and incubated at 37℃ for 48 hours. Samples cultured in MRS medium were used as a negative control. The supernatant of the cultures obtained by centrifugation (4,500 rpm, 20 minutes, 4℃) was saponified by adding 0.5 mL saponification reagent (50 g of potassium hydroxide, 400 mL isopropanol, 600 mL distilled water) followed by 0.5 mL of acetylacetone reagent (0.75 mL of acetylacetone, 40 mL of isopropanol, 60 mL distilled water). Evenly mixed mixtures were kept at 65℃ for 1 hour in an oil bath and cooled. The blank control and a series of standard concentrations of triolein were treated using the same method, and absorbance at 420 nm was read: C×T=cholesterol reduction rate (%)×TG reduction rate (%).

Polysaccharides from Dendrobium officinale, Talinum triangulare, and other sources were prepared according to the report [25]. Briefly, the D. officinale or other medicinal plant powder (20 g) was boiled three times with 600 mL distilled water for 3 hours. The polysaccharide was obtained by ethanol precipitation. After an 8-hour fast, mice were injected with glucose (3 g/kg), and after 15 minutes of glucose loading, an equal amount of polysaccharides was given by intragastric administration for 4 weeks. After the last administration, all the mice were fasted strictly but allowed free access to water as usual for 4 hours. Blood was collected for measurement of fasting glucose and insulin levels 12 hours after the last polysaccharide administration.

An insulin enzyme-linked immunosorbent assay (ELISA) kit (TSZ, San Francisco, CA, USA) was used to determine the fasting insulin (FINS). To select the polysaccharide with a good performance on reducing insulin resistance, the insulin sensitivity index (ISI) was calculated according to the following formulas: ISI=Ln [1/(FBG×FINS)] [2627], where FBG was the level of fasting blood glucose (mg/dL) and FINS was the level of FINS (mIU/L). The index of insulin resistance was calculated by the following formulas [28]: homeostasis model assessment of insulin resistance (HOMA-IR)=FINS (mIU/L)×FBG (mmol/L)/22.5.

Screening and identification of the candidate strains

The effect of bile salts on the growth of these tested strains was carried out using a method described by Bao et al. [29]. After culturing in MRS broth at 37℃ for 12 hours, the bacterial concentration was adjusted to 10⁸ colony-forming unit (CFU)/mL. Afterward, samples were inoculated into (1%, v/v) MRSB broth (MRS broth supplemented with 0.3% bile salts [oxgall]). Samples inoculated into MRS broth were used as controls. Strains were incubated anaerobically at 37℃ for 24 hours. To monitor bacterial growth, the optical density (OD_620nm) was measured with a spectrophotometer. Survival percentage (%)=S/S_o×100%, where S was the OD_620nm of the MRSB culture and S_o was the OD_620nm of the MRS culture (control). Genomic DNA of the strain was extracted and amplified by polymerase chain reaction (PCR) according to the method of Huang et al. [30]. After cloning, the candidate strains were identified by DNA sequencing (Sangon Biotech, Shanghai, China) [31], and the sequence was compared to the National Center for Biotechnology Information (NCBI) database.

Oral glucose tolerance test and insulin tolerance test

Oral glucose tolerance tests (OGTTs) were measured at 0 to 6 weeks after treatments. Glucose load (2.0 g/kg of body weight) was conducted after 12 hours of fasting by oral gavage. After glucose administration, blood samples were collected at 0, 15, 30, 60, 90, and 120 minutes. Concentrations of glucose were measured, and the total glucose area under the curve (AUC_glucose) were calculated. The insulin tolerance test (ITT) was completed after 6 hours of fasting. Next, 1.5 IU/kg insulin was infused into mice, and glucose was measured intraperitoneally. The constant rate for glucose disappearance during the ITT (K_ITT) was calculated using the formula 0·693/t_1/2, where t_1/2 was calculated from the slope of the least square analysis of the blood glucose levels during the linear decay phase of decline.

Mice and treatments

Forty male C57BL/6N mice (pathogen-free) were purchased from the Shanghai Laboratory Animal Center (Shanghai, China). The average initial body weight of the mice was approximately 18.5 g. The mice were housed in clean, sterile, polypropylene cages under controlled conditions with a room temperature of 20℃ to 24℃ and a cycle of 12/12 hours light-dark. Moreover, the experimental group and the control group were housed under the same conditions. During the first week, all mice were fed the same normal diet (ND). Afterward, the mice were randomly divided into four groups (n=10/group). The ND group received the normal diet, while the HFD group received the HFD diet; the HFD+(L. plantarum X [LpX]-B. bifidum V [BbV] [LB]) group received an HFD diet supplemented with LB via intragastric administration, and the HFD+(LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide [LBM]) group received an HFD supplemented with LBM via intragastric administration. LB was a mixture of 1×10⁸ CFU/mL of LpX and 2×10⁸ CFU/mL BbV; LBM was composed of LB (1×10⁸ CFU/mL LpX+2×10⁸ CFU/mL BbV) plus S. miltiorrhiza Bunge polysaccharide (50 mg/kg/day). After 30 minutes of LB administration, S. miltiorrhiza Bunge polysaccharide was given by intragastric administration. After the end of the experiment, all mice were sacrificed after fasting for 12 hours. The mice's livers were collected, weighed and stored at −80℃. For bacterial DNA and RNA extraction, the small intestinal and liver were frozen immediately in liquid nitrogen. All animal experiments were approved by the Ethics Committee of Southern Medical University Affiliated Nanfang Hospital (approval no. 20180415-NF325). All animal treatments were carried out in accordance with the Guidelines on Care and Use of Laboratory Animals issued by the Chinese Council on Animal Research and the Guidelines of Animal Care.

Measurement of biochemical parameters in the serum and liver

The mice were sacrificed by cervical dislocation. The mice's liver homogenate (1 g of liver tissue and 10 mL of sterilizing saline) was added into Folch solution (chloroform: formaldehyde=2:1 [v/v]), mixed well and centrifuged (4,500 ×g, 5 minutes). The supernatant of the liver was collected. The levels of high density lipoprotein cholesterol (HDL-C) and TC, TG and ASTase activity and ALTase activity were determined using test kits (Biosino Biotechnology and Science Inc., Beijing, China). Endotoxin levels (lipopolysaccharide [LPS]) were measured by using a limulus amebocyte lysate (LAL) assay endotoxin assay kit (Charles River Lab, Wilmington, MA, USA). The concentrations of acetate and butyrate were analyzed by Agilent 1260 Infinity high-performance liquid chromatography (HPLC; Agilent, Santa Clara, CA, USA) according to the report of Adler et al. [32].

Reverse-transcription quantitative polymerase chain reaction

Total RNA of the collected tissue was extracted by using a TranZol RNA Extraction Kit (Trans Gen Biotech, Beijing, China). Afterward, cDNA was obtained from the total RNA by reverse transcription using a cDNA synthesis kit (Takara Bio, Dalian, China). Interleukin 1β (IL-1β), TNF-α, and IL-6 were completed by using SYBR premix from Takara Bio. Primer sequences used for mRNA quantification are presented in Supplementary Table 1.

Sequences of the primers used in the lipid metabolism gene detection are presented in Supplementary Table 2. Fecal DNA was isolated using the QIAmp DNA stool mini kit (Qiagen, Hilden, Germany). Quantitative PCR analysis was performed using different genus- and phyla-specific primers for different bacterial groups according to the Kump et al. [33].

Statistical analysis

The software package SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis. All data are presented as the mean±standard deviation, and statistical significance was performed by one-way analysis of variance (ANOVA) followed by least significant difference for multiple comparisons. P values less than 0.05 were considered to be statistically significant.

RESULTS

Screening of probiotics from the fecal microbiota of healthy adults

High levels of cholesterol and TGs were associated with the formation of hyperlipidemia [34]. To obtain the strain with a highly effective lipid-lowering function, 47 candidates isolated from fecal samples were examined. The results are shown in Fig. 1A. Isolate V exhibited the highest activity on TG clearance (68% TG clearance, 25% CC). The IX isolate showed the highest activity on CC. Interestingly, isolate X exhibited outstanding performance, with cholesterol and TG clearance of 57% and 53%, respectively. The selected candidate isolates (X, IX, V) were cultured in the simulated gastric fluid. Fortunately, the survival rates of isolates V and X were up to 87.4% and 78.6%, respectively. However, the IX isolates had relatively low bile resistance (survival rates <20%). Meanwhile, Δlag phase of the tested isolates was investigated. The results showed that the growth of isolates X was slower than that of isolates V with a long Δlag phase of 2.1 hours (Fig. 1B). Based on the 16S rDNA sequence identification, strain V, X was B. bifidum and L. plantarum, respectively. To enhance the performances of the strains synergistically, the ratio of LB was optimized in vitro. The result showed that the cholesterol-TG clearance rate was up to the highest with a C×T value of 0.47, while the ratio of LB was 1:2 (Fig. 1C).

Insulin resistance is a cardinal feature of NAFLD [35]. Insulin resistance plays an important role during the development of NAFLD and progression to NASH [36]. To increase insulin sensitivity, polysaccharides derived from different sources were screened. The results showed that most of the tested polysaccharides can improve insulin resistance. In particular, compared to the other sources, the S. miltiorrhiza Bunge polysaccharide showed good performance with an ISI value of −4.26 was selected to reduce insulin resistance (Fig. 1D). Next, 50 mg/kg/day S. miltiorrhiza Bunge polysaccharide was observed to improve insulin resistance (Fig. 1E).

Effects of probiotic combination (LBM) on body index

After HFD-induced treatment, the liver weight and body weight in the HFD group mice were significantly higher than those fed the ND. However, after LB or LBM treatment, a reduction in body weight was observed (Table 1, Fig. 1F). The total body weight of the LB group and LBM group was reduced by 12.5% and 21.5%, respectively, compared to the HFD mouse models. This weight loss was not related to reduced food intake (Fig. 1G) [37]. In addition, compared to the HFD group, a significant reduction of the liver was observed in the HFD+LB group. Moreover, S. miltiorrhiza Bunge polysaccharide contributed to reducing the liver index values of HFD groups; however, the promoting effect was not significant (Table 1). The liver TC levels and liver TG levels were increased in the HFD group compared to the control group. In contrast, the liver TC and TG levels can be decreased by LB (1:2) in mice fed a HFD (Fig. 2A and B). The lipids can be reduced by LB or LBM, where the increased total short-chain fatty acid concentration (the metabolism products of lipids) in cecal content has been observed (Fig. 2D). After 6 weeks of HFD consumption, the mice showed increased glucose blood levels and insulin resistance. After LB or LBM treatment, the blood glucose levels were reduced (close to the control group), and the insulin resistance was improved. Compared to the HFD group, HOMA-IR in the LBM group was reduced by 66.3%, LBM has the potential to reduce insulin resistance and improve insulin sensitivity (Fig. 2E, F, and J). In addition, NAFLD mice fed with LB (1:2) promoted excretion of cholesterol and total bile acid (Fig. 2C). Insulin sensitivity, as determined by the glucose disappearance rate (KITT) (Fig. 2I), ISI, or HOMA-IR (Fig. 2F and J), was decreased in HFD group mice and showed improvement after LB or LBM treatment. In the OGTT, the blood glucose increased to a maximum after 30 minutes of oral administration of glucose in all groups (Fig. 2G and H). This increased blood glucose in the HFD group was significantly decreased after administration of LBM (Fig. 2G). The inhibitory effect of LBM on blood glucose elevation by HFD treatment has been clearly reflected by the AUC_glucose values (Fig. 2H).

Effects of probiotic combination (LBM) on lipid profiles

The results showed that the serum TC, low density lipoprotein cholesterol (LDL-C), and TG levels of the HFD group decreased significantly by treatment with probiotic LB (1:2) (Table 2). Compared to the ND group, the HDL level decreased significantly in the HFD group. In contrast, the HDL level of HFD-treated mice increased when supplemented with LB (1:2). Furthermore, serum free fatty acid (FFA), ALTase, ASTase, LDL-C, TG and TC levels in the HFD group were reduced by supplementation with LBM significantly.

Effect of combination (LBM) on gut microbiota

The relative abundance of gut microbiota at the phylum and genus levels was investigated. For the ND group, Firmicutes and Bacteroidetes (with 80% to 90% abundance) were the main members of the gut bacteria community presenting in the feces at the phylum level. Moreover, compared to the ND group, the abundance of Cyanobacteria was increased by 68.75% in the HFD group (Fig. 3A). After administering the probiotic combination (LBM), the abundance of Cyanobacteria in HFD-fed mice was reduced.

Moreover, the ratio of Bacteroidetes/Firmicutes in the HFD group decreased by 42.6% compared to the ND group. However, the ratio of Bacteroidetes/Firmicutes was increased by 14.3% and 34.04% relative to the HFD group via administration probiotics LB and LBM, respectively. At the genus level, the expression profiles of each group (16 highly abundant species >1.0% abundance), including the abundance of Bacteroides, Lactobacillus, Parabacteroides, Oscillospira, and Alistipes, were analyzed (Fig. 3B). Of those species, the abundance of Bacteroides, Lactobacillus, and Parabacteroides was increased by treatment with LB probiotics, while the Oscillospira and Alistipes were decreased by LBM.

Effects of probiotic combination (LBM) on endotoxin and liver inflammation

The concentrations of acetate, butyrate, and LPS were investigated. The total concentrations of acetate and butyrate were significantly reduced by 81.7% and 80% in the HFD groups compared to the ND group. The acetate and butyrate concentrations of NAFLD mice were increased by supplementation with LBM (Fig. 4A and B). Moreover, the HFD group with a high LPS concentration was significantly reduced by probiotic (LB). Moreover, the ability of probiotic LB was enhanced by S. miltiorrhiza Bunge polysaccharide, the LPS concentration of LB group (0.23 endotoxin unit [EU]/mL) decreased by 73.6% compared to the HFD group (0.87 EU/mL); however, the difference between LB and LBM is not significant (P>0.05) (Fig. 4C).

Based on the changes in short-chain organic acid concentrations and gut microbial abundance in HFD-treated mice, we were trying to reveal the global influence of LBM on liver inflammation. Inflammatory markers (TNF-α, IL-1β, and IL-6) of the liver were investigated. The results showed that inflammatory markers were modulated by the probiotic combination (LBM). Compared to the HFD group, the mRNA concentrations of cytokines (TNF-α, IL-1β, IL-6) were reduced by LB and LBM (Fig. 4D). Interestingly, the TNF-α concentration in the LBM group was significantly lower than that in the ND group.

The effect of LBM on lipid metabolism was investigated (Fig. 4E), and the results are shown in Fig. 4F. In the way of de novo synthesis, increased hepatic expression of the four genes (acetyl-CoA carboxylase [ACC], fatty acid synthase [FAS], stearoyl-CoA desaturase-1 [SCD-1], and sterol regulatory element binding protein 1c [SREBP-1c]) in the HFD group was observed compared with the ND group. The hepatic expression of ACC, FAS, and SREBP-1c was clearly reduced after LBM treatment. The change in SCD-1 gene expression between the HFD group and the HFD supplemented with LB or LBM group was not significant (P>0.05). Compared to the HFD group, a significant decrease in the hepatic expression of SREBP-1c was induced by LBM (P<0.01) (Fig. 4E and F). Regarding oxidation metabolism, genes associated with fatty acid oxidation (peroxisome proliferator-activated receptor-α [PPARα] and carnitine palmitoyltransferase-1a [CPT-1a]) showed a significant improvement with the help of LBM (P<0.05) (Fig. 4F).

DISCUSSION

Blood cholesterol can be reduced by various strains of Lactobacilli and Bifidobacteria, which is safe for consumption, such as Lactobacilli rhamnosus, L. paracasei, L. casei, and L. plantarum [3839]. Fecal microbiota transplantation has been used for the treatment of Clostridium difficile-associated diarrhea and pseudomembranous colitis [40], which highlighted a disease improvement or resolution rate of 83% to 92% [41]. Therefore, the fecal microbiota of healthy adults was selected for the screening of probiotics (Lactobacillus), and most of the isolates performed a high CC capability in this study.

In addition, insulin resistance has been regarded as a key factor in the pathogenesis of metabolic syndrome [11]. Hepatocyte injury and inflammation could be promoted by hepatic insulin resistance [1642]. It has been reported that different sources of polysaccharides (such as Ganoderma lucidum) could improve insulin resistance by regulating gut microbiota composition and inflammatory cytokines [43]. In the present study, different polysaccharides were screened, and the insulin sensitivity was improved by polysaccharides from S. miltiorrhiza Bunge, which was the outstanding performer among the tested polysaccharides. Finally, the FFA, ALTase, ASTase, LDL-C, TG and TC levels of HFD-treated mice in serum were significantly reduced by LB (1:2). The function of the probiotic LB was enhanced by S. miltiorrhiza Bunge polysaccharide. In previous research, polysaccharides have been used to reduce IL-6, IL-1β, and TNF-α concentrations in plasma [43]. TNF-α expression and hepatic inflammation can be reduced by L. rhamnosus and other probiotics [44]. Our research showed that the expression levels of TNF-α, IL-1β, and IL-6 can be reduced by LBM; we speculate that it was the result of the synergy between L. plantarum-B. bifidum and S. miltiorrhiza Bunge. Furthermore, it was shown that the composition of the intestinal microbiota can be regrouped by LBM in this study. The abundance of Cyanobacteria in HFD-fed mice was reduced by administering LBM. Previous studies indicated that microbiota composition is related to insulin resistance. Increased Cyanobacteria (gram-negative bacteria) have been demonstrated as contributors to increased LPS levels, and all types of Cyanobacteria can produce various toxins, which are involved in various human diseases via increasing the hepatic damage triggered by hepatotoxins [45]. Moreover, we found that Bacteroidetes/Firmicutes can be increased by LB and LBM. Numerous studies have suggested that Firmicutes/Bacteroidetes ratios are a compositional biomarker for obesity [46] and type 1 diabetes mellitus [47]. Moreover, fecal extracts of ulcerative colitis patients were characterized by reduced levels of butyrate, acetate, methylamine, and trimethylamine in comparison with a control population [4849]. The acetate and butyrate concentrations of NAFLD mice were increased by supplementation LBM in this study. This result was consistent with the report of Turnbaugh et al. [49] and de Wit et al. [50]. Therefore, LBM combination has the potential to be used as a therapeutic for ameliorating NAFLD via modulation of the gut microbiota and improvement of insulin resistance.

Acknowledgements

ACKNOWLEDGMENTS

Funding for this study was provided by the Chinese Foundation for Hepatitis Prevention and Control–TianQing Liver Disease Research Fund Subject TQGB20190130 (http://www.cfhpc.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS:

• Conception or design: W.W., F.C.Z.

• Acquisition, analysis, or interpretation of data: Y. L., S.F.X.

• Drafting the work or revising: W.W., A.L.X., Z.C.L.

• Final approval of the manuscript: H.C.S., F.C.Z.

SUPPLEMENTARY MATERIALS

REFERENCES

• 1. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 2016;9:65-90. ArticlePubMedPMCPDF
• 2. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23:203-208. ArticlePubMed
• 3. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-1922. ArticlePubMed
• 4. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-665. ArticlePubMedPDF
• 5. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:691-701. ArticlePubMedPDF
• 6. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725. ArticlePubMed
• 7. Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol 2015;7:1450-1459. ArticlePubMedPMC
• 8. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-1560. ArticlePubMedPMC
• 9. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-690. ArticlePubMedPDF
• 10. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000;119:1340-1347. ArticlePubMed
• 11. Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, Wada N, Kurita Y, Tanaka K, Hara K, Soejima E, Tajiri Y, Yamada K. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res 2018;50:80-87. ArticlePubMed
• 12. Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002;97:2364-2370. ArticlePubMed
• 13. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001;96:1251-1255. ArticlePubMed
• 14. Thalheimer U, De Iorio F, Capra F, del Mar Lleo M, Zuliani V, Ghidini V, Tafi MC, Caburlotto G, Gennari M, Burroughs AK, Vantini I. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol 2010;22:1228-1234. ArticlePubMed
• 15. Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B, de la M Hall P. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 2006;21:174-182. ArticlePubMed
• 16. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372. ArticlePubMedPDF
• 17. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, Wells JM. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010;298:G851-G859. ArticlePubMed
• 18. Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr 2012;50:72-77. ArticlePubMed
• 19. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013;19:6911-6918. ArticlePubMedPMC
• 20. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012;57:545-553. ArticlePubMedPDF
• 21. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009;15:1546-1558. ArticlePubMed
• 22. Azat R, Liu Y, Li W, Kayir A, Lin DB, Zhou WW, Zheng XD. Probiotic properties of lactic acid bacteria isolated from traditionally fermented Xinjiang cheese. J Zhejiang Univ Sci B 2016;17:597-609. ArticlePubMedPMCPDF
• 23. Mei L, Tang Y, Li M, Yang P, Liu Z, Yuan J, Zheng P. Co-Administration of cholesterol-lowering probiotics and anthraquinone from Cassia obtusifolia L. Ameliorate non-alcoholic fatty liver. PLoS One 2015;10:e0138078. ArticlePubMedPMC
• 24. Saravanan G, Ponmurugan P. Ameliorative potential of S-allylcysteine: effect on lipid profile and changes in tissue fatty acid composition in experimental diabetes. Exp Toxicol Pathol 2012;64:639-644. ArticlePubMed
• 25. Zhang W, Zheng L, Zhang Z, Hai CX. Protective effect of a water-soluble polysaccharide from Salvia miltiorrhiza Bunge on insulin resistance in rats. Carbohydr Polym 2012;89:890-898. ArticlePubMed
• 26. Xing XY, Li YF, Fu ZD, Chen YY, Wang YF, Liu XL, Liu WY, Li GW. Antihypertensive effect of metformin in essential hypertensive patients with hyperinsulinemia. Zhonghua Nei Ke Za Zhi 2010;49:14-18. PubMed
• 27. Zhang Y, Hu T, Zhou H, Zhang Y, Jin G, Yang Y. Antidiabetic effect of polysaccharides from Pleurotus ostreatus in streptozotocin-induced diabetic rats. Int J Biol Macromol 2016;83:126-132. ArticlePubMed
• 28. Ren D, Hu Y, Luo Y, Yang X. Selenium-containing polysaccharides from Ziyang green tea ameliorate high-fructose diet induced insulin resistance and hepatic oxidative stress in mice. Food Funct 2015;6:3342-3350. ArticlePubMed
• 29. Bao Y, Zhang Y, Zhang Y, Liu Y, Wang S, Dong X, Wang Y, Zhang H. Screening of potential probiotic properties of Lactobacillus fermentum isolated from traditional dairy products. Food Control 2010;21:695-701.Article
• 30. Huang Y, Wang X, Wang J, Wu F, Sui Y, Yang L, Wang Z. Lactobacillus plantarum strains as potential probiotic cultures with cholesterol-lowering activity. J Dairy Sci 2013;96:2746-2753. ArticlePubMed
• 31. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol 2007;45:2761-2764. ArticlePubMedPMCPDF
• 32. Adler P, Frey LJ, Berger A, Bolten CJ, Hansen CE, Wittmann C. The key to acetate: metabolic fluxes of acetic acid bacteria under cocoa pulp fermentation-simulating conditions. Appl Environ Microbiol 2014;80:4702-4716. ArticlePubMedPMCPDF
• 33. Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, Hogenauer C. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013;19:2155-2165. ArticlePubMed
• 34. Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996;7:341-355. ArticlePubMed
• 35. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-4761. PubMed
• 36. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-8638. ArticlePubMedPMC
• 37. Ding W, Shi C, Chen M, Zhou J, Long R, Guo X. Screening for lactic acid bacteria in traditional fermented Tibetan yak milk and evaluating their probiotic and cholesterol-lowering potentials in rats fed a high-cholesterol diet. J Funct Foods 2017;32:324-332.Article
• 38. Ooi LG, Liong MT. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 2010;11:2499-2522. ArticlePubMedPMC
• 39. Liu W, Xi X, Sudu Q, Kwok L, Guo Z, Hou Q, Menhe B, Sun T, Zhang H. High-throughput sequencing reveals microbial community diversity of Tibetan naturally fermented yak milk. Ann Microbiol 2015;65:1741-1751.ArticlePDF
• 40. Palmer R. Fecal matters. Nat Med 2011;17:150-152. ArticlePubMedPDF
• 41. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53:994-1002. ArticlePubMed
• 42. Farrell GC. Signalling links in the liver: knitting SOCS with fat and inflammation. J Hepatol 2005;43:193-196. ArticlePubMed
• 43. Xu S, Dou Y, Ye B, Wu Q, Wang Y, Hu M, Ma F, Rong X, Guo J. Ganoderma lucidum polysaccharides improve insulin sensitivity by regulating inflammatory cytokines and gut microbiota composition in mice. J Funct Foods 2017;38(Pt A):545-552.Article
• 44. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-G1036. ArticlePubMedPMC
• 45. Durai P, Batool M, Choi S. Structure and effects of cyanobacterial lipopolysaccharides. Mar Drugs 2015;13:4217-4230. ArticlePubMedPMC
• 46. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-1023. ArticlePubMedPDF
• 47. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008;455:1109-1113. ArticlePubMedPMCPDF
• 48. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, Wilson ID, Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007;6:546-551. ArticlePubMed
• 49. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031. ArticlePubMedPDF
• 50. de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, de Vogel-van den Bosch J, Kleerebezem M, Muller M, van der Meer R. Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 2012;303:G589-G599. ArticlePubMed

Fig. 1

(A) Strains screening. (B) The survival rate of three isolates in MRSB broth (MRS [de MAN, ROGOSA and SHARPE] broth containing 0.3% bile salts). (C) Effect of the ratio of Lactobacillus plantarum to Bifidobacterium bifidum on cholesterol-triglyceride reduction. (D) Effect of different polysaccharides on insulin resistance. (E) Effect of Salvia miltiorrhiza Bunge polysaccharide (M) dose on the insulin sensitivity index (ISI). The changes in (F) body weight and (G) food intake for 6 weeks. Food intake was estimated using the following formulas: Food intake=(initial weight of food provided–the final weight of food recovered [g]). MRSB was MRS broth supplemented with 0.3% bile salts after 3 hours at 37℃. The Δlag phase was calculated as the time needed to increase by 0.5 absorbance units at 620 nm in MRSB minus the time requirement in MRS broth according to Ding et al. [37]. C×T=cholesterol reduction rate (%)×triglyceride reduction rate (%). The ISI was calculated according to the following formulas: ISI=Ln [1/(FBG×FINS)], where FBG was the level of fasting blood glucose (mmol/L) and FINS was the level of fasting insulin (mU/L). All measurements were taken in triplicate, and experiments were repeated three times to evaluate the standard deviation. LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide; L. barbarum, Lycium barbarum; P. linteus, Phellinus linteus; M. charantia L., Momordicacharantia L.; C. militaris, Cordyceps militaris; A. membranaceus, Astragalus membranaceus (Fisch.) Bunge; S. miltiorrhiza, S. miltiorrhiza Bunge. ^aP<0.05, ^bP<0.01 indicates statistically significant differences compared with the high-fat diet (HFD) group (control), ^cP<0.01 indicates statistically significant differences compared with the normal diet (ND) group (control).

Fig. 2

Liver (A) total cholesterol (TC) and (B) triglyceride (TG) levels in mice with different treatments. (C) Fecal TC of the four groups at the end of feeding period, mice orally fed high-fat diet (HFD) supplemented with a mixture of L. plantarum-B. bifidum (1:2) and Salvia miltiorrhiza Bunge polysaccharide. (D) Total short-chain fatty acid concentration (the metabolized products of lipids) in cecal content. (E) Serum insulin; (F) fasting blood glucose (FBG). (G) Oral glucose tolerance test (OGTT) at 6 weeks after treatment and (H) the area under the curve (AUC) of OGTT at 6 weeks. (I) The glucose disappearance rate during the insulin tolerance test (K_ITT). (J) Homeostasis model assessment of insulin resistance (HOMA-IR). Insulin sensitivity index (ISI)=−ln (FPG×fasting insulin [FINS]). HOMA-IR=FINS (mIU/L)×FBG (mmol/L)/22.5. Data are expressed as the mean±standard deviation. ND, normal diet; LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide. ^aP<0.05, ^bP<0.01.

Fig. 3

Effect of probiotic combination (LBM) on gut microbiota in the intestines of tested mice. (A) The relative abundance of four groups at the phyla level and (B) the relative abundance of four groups at the genus level. ND, normal diet; HFD, high-fat diet; LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide.

Fig. 4

Effect of probiotic combination LBM on the concentration of short-chain organic acids and endotoxin (lipopolysaccharide [LPS]) in cecal content. (A) Levels of butyrate in cecal content, (B) levels of acetate in cecal content, (C) LPS, (D) mRNA expression of inflammatory genes in the liver of mice. (E, F) Effect of LBM on the expression of the beginning synthesis genes and lipid oxidation genes. Relative mRNA levels are expressed as a ratio relative to β-actin. Values are expressed as the mean±standard deviation. ND, normal diet; HFD, high-fat diet; LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide; TNF-α, tumor necrosis factor α; IL-1β, interleukin 1β; IL-6, interleukin 6; FAS, fatty acid synthase; ACC, acetyl-CoA carboxylase; SREBP-1c, sterol regulatory element binding protein 1c; SCD-1, stearoyl-CoA desaturase-1; PPARα, peroxisome proliferator-activated receptor-α; CPT-1a, carnitine palmitoyltransferase-1a. ^aP<0.05, ^bP<0.01.

Table 1

Body weight gain, liver weight, and liver index of mice in four groups

Group	BW gain, g	Liver weight, mg	Liver/BW, mg/g
ND	7.92±0.42	1,030.00±20.1	38.66±0.35
ND+LB	7.88±0.35	1,029.00±18.5	38.76±0.30
ND+LBM	7.82±0.27	1,031.00±19.0	39.05±0.26
HFD	18.50±0.88	2,110.00±35	56.72±2.25
HFD+LB	14.00±0.49	1,324.00±8.5	40.68±0.58
HFD+LBM	10.55±0.43	1,128.00±6.5	38.64±0.31

Values are presented as mean±standard deviation. Liver index (liver/BW)=liver weight/final BW.

BW, body weight; ND, normal diet; LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide; HFD, high-fat diet.

Table 2

Serum lipid levels in the four groups

Group	TG, mg/dL	TC, mg/dL	LDL-C, mg/dL	HDL-C, mg/dL	ALTase, U/L	ASTase, U/L
ND	92.9±1.0	84.7±0.58	25.9±0.15	57.5±0.6	26.3±0.5	55.1±1.2
HFD	115.1±2.1	168.5±3.2	65.5±0.82	25.9±2.1	83.5±2.5	128.5±12.2
HFD+LB	104.7±1.5	114.3±2.5	39.8±0.40	55.8±1.7	34.9±1.2	68.2±2.9
HFD+LBM	101.2±1.5	100.1±1.2	38.2±0.25	62.7±2.4	23.8±1.1	62.5±1.2

Values are presented as mean±standard deviation.

TG, triglyceride; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ALTase, alanine transaminase; ASTase, aspartate transaminase; ND, normal diet; HFD, high-fat diet; LB, Lactobacillus plantarum X (LpX)-Bifidobacterium bifidum V (BbV); LBM, LpX-BbV+Salvia miltiorrhiza Bunge polysaccharide.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Bifidobacterium bifidum BGN4 fractions ameliorate palmitic acid-induced hepatocyte ferroptosis by inhibiting SREBP1-CYP2E1 pathway
  Guangkui Bu, Gang Chen, Juan Li, Dan Wu, Jiangtao Liao
  Journal of Investigative Medicine.2024; 72(1): 67.     CrossRef
• Docosahexaenoic acid (DHA) alleviates hepatic lipid accumulation by regulating mitochondrial quality control through ERK signaling pathway in grass carp (Ctenopharyngodon idellus)
  Chenchen Bian, Shanghong Ji, Caihong Zeng, Jian Sun, Gen Kaneko, Hong Ji
  Aquaculture.2024; 579: 740209.     CrossRef
• Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study
  Lubo Shi, Xiaoduo Liu, Enze Li, Shutian Zhang, Anni Zhou
  Journal of Clinical Lipidology.2024;[Epub]     CrossRef
• Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity
  Oladayo Emmanuel Apalowo, Grace Adeola Adegoye, Tolulope Mobolaji Obuotor
  Current Issues in Molecular Biology.2024; 46(3): 1810.     CrossRef
• Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
  Qingyi Mao, Beibei Lin, Wenluo Zhang, Yu Zhang, Yu Zhang, Qian Cao, Mengque Xu
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Smilax China L. polysaccharide prevents HFD induced-NAFLD by regulating hepatic fat metabolism and gut microbiota
  Wenkai Zhang, Longhui Yu, Qinru Yang, Jinfeng Zhang, Wenjing Wang, Xinru Hu, Jingen Li, Guodong Zheng
  Phytomedicine.2024; 127: 155478.     CrossRef
• Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
  Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova
  Gut Microbes.2024;[Epub]     CrossRef
• Prospect of research on anti-atherosclerosis effect of main components of traditional Chinese medicine Yiqi Huoxue Huatan recipe through gut microbiota: A review
  Hongtao Huang, Hanjun Zhao, Lv Wenqing, Feiyue Xu, Xiaolong Wang, Yili Yao, Yu Huang
  Medicine.2024; 103(5): e37104.     CrossRef
• Polysaccharides from Eucommia ulmoides Oliv. Leaves Alleviate Acute Alcoholic Liver Injury by Modulating the Microbiota–Gut–Liver Axis in Mice
  Yingzhi Li, Huimei Wang, Xueping Leng, Jiaming Gao, Chang Li, Danfei Huang
  Foods.2024; 13(7): 1089.     CrossRef
• Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
  Feng Zhang, Jiaming Ju, Hongtao Diao, Jinglun Song, Yu bian, Baofeng Yang
  British Journal of Pharmacology.2024;[Epub]     CrossRef
• Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites
  Dongliang Chen, Yuanfei Wang, Jianmei Yang, Wanyi Ou, Guiru Lin, Ze Zeng, Xiaomin Lu, Zumin Chen, Lili Zou, Yaling Tian, Aiping Wu, Shelley E. Keating, Qinhe Yang, Chenli Lin, Yinji Liang
  Frontiers in Pharmacology.2024;[Epub]     CrossRef
• Berberine alleviates high-energy and low-protein diet-induced fatty liver hemorrhagic syndrome in laying hens: insights from microbiome and metabolomics
  Xinyi Cheng, Yang Hu, Jun Kuang, Xiaoquan Guo, Huabin Cao, Huansheng Wu, Guoliang Hu, Yu Zhuang
  Poultry Science.2024; 103(8): 103968.     CrossRef
• Gut–Liver–Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies
  Giada Marroncini, Laura Naldi, Serena Martinelli, Amedeo Amedei
  Biomedicines.2024; 12(7): 1398.     CrossRef
• The molecular and network mechanisms of antilipidemic potential effects of Ganfule capsules in nonalcoholic fatty liver disease
  Yu Pan, Liya Qiao, Yunkun Zhang, Suren R. Sooranna, Danna Huang, Min Ou, Fei Xu, Lu Chen, Dan Huang
  Heliyon.2024; 10(14): e34297.     CrossRef
• Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators
  Lara Pires, Ana M. González-Paramás, Sandrina A. Heleno, Ricardo C. Calhelha
  Antibiotics.2024; 13(8): 720.     CrossRef
• Polysaccharide-mediated modulation of gut microbiota in the treatment of liver diseases: Promising approach with significant challenges
  Yang Yang, Guifang Fan, Jianhang Lan, Xin Li, Xiaojiaoyang Li, Runping Liu
  International Journal of Biological Macromolecules.2024; 280: 135566.     CrossRef
• Network analysis and experimental verification of Salvia miltiorrhiza Bunge-Reynoutria japonica Houtt. drug pair in the treatment of non-alcoholic fatty liver disease
  Huafeng Chen, Shengzhe Yan, Qianru Xiang, Jiamin Liang, Xuejian Deng, Wanqin He, Yanzhen Cheng, Li Yang
  BMC Complementary Medicine and Therapies.2024;[Epub]     CrossRef
• Protective effects of Nogo-B deficiency in NAFLD mice and its multiomics analysis of gut microbiology and metabolism
  Xu Dong, Yu-Ting Xiong, Tingting He, Congyang Zheng, Junjie Li, Yingjie Zhuang, Yingjie Xu, Ye Xiu, Zhixin Wu, Xiaomei Zhao, Xiaohe Xiao, Zhaofang Bai, Lili Gao
  Genes & Nutrition.2024;[Epub]     CrossRef
• Polysaccharide of Atractylodes macrocephala Koidz alleviates NAFLD-induced hepatic inflammation in mice by modulating the TLR4/MyD88/NF-κB pathway
  Junyi Chen, Shuzhan Yang, Hanxia Luo, Xinliang Fu, Wanyan Li, Bingxin Li, Cheng Fu, Feiyue Chen, Danning Xu, Nan Cao
  International Immunopharmacology.2024; 141: 113014.     CrossRef
• Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
  Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
  Chinese Journal of Natural Medicines.2024; 22(8): 724.     CrossRef
• Therapeutic Role of Probiotics Against Environmental-Induced Hepatotoxicity: Mechanisms, Clinical Perspectives, Limitations, and Future
  Shehzeen Noor, Shaukat Ali, Muhammad Summer, Anfah Riaz, Laiba Nazakat, Aqsa
  Probiotics and Antimicrobial Proteins.2024;[Epub]     CrossRef
• Danshen polysaccharides alleviate AFB1 induced Jejunal injury
  Lu Zhang, Xincheng Gong, Shijia Zhang, Chanchan Cui, Qiongyi Zhang, Xiao Wang, Wanyu Shi, Yongzhan Bao
  Ecotoxicology and Environmental Safety.2024; 285: 117115.     CrossRef
• Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis
  Hui Han, Yi Jiang, Mengyu Wang, Mebratu Melaku, Lei Liu, Yong Zhao, Nadia Everaert, Bao Yi, Hongfu Zhang
  Critical Reviews in Food Science and Nutrition.2023; 63(12): 1689.     CrossRef
• Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance
  Clement Agboyibor, Jianshu Dong, Clement Yaw Effah, Emmanuel Kwateng Drokow, Maxwell Ampomah-Wireko, Waqar Pervaiz, Augustina Sangmor, Xinli Ma, Jian Li, Hong-Min Liu, Peng Zhang
  Biomedicine & Pharmacotherapy.2023; 157: 113934.     CrossRef
• Salvia miltiorrhiza polysaccharides alleviate florfenicol-induced inflammation and oxidative stress in chick livers by regulating phagosome signaling pathway
  Xiao Wang, Wei Liu, Di Zhang, Yulan Jiao, Qianhui Zhao, Ying Liu, Wanyu Shi, Yongzhan Bao
  Ecotoxicology and Environmental Safety.2023; 249: 114428.     CrossRef
• Preparation methods, structural characteristics, and biological activity of polysaccharides from Salvia miltiorrhiza: A review
  Yuanyuan Li, Xin Zhang, Yining Li, Pei Yang, Zhiyuan Zhang, Hang Wu, Lihao Zhu, Yuhong Liu
  Journal of Ethnopharmacology.2023; 305: 116090.     CrossRef
• The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial
  Dengcheng Hui, Lu Liu, Nisma Lena Bahaji Azami, Jingru Song, Yanping Huang, Wan Xu, Chao Wu, Dong Xie, Yulang Jiang, Yanqin Bian, Mingyu Sun
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases
  Xiaoyu Huang, Yi Yang, Xueli Li, Xiaoya Zhu, Dan Lin, Yueran Ma, Min Zhou, Xiangyi Cui, Bingyu Zhang, Dongmei Dang, Yuhong Lü, Changwu Yue
  Frontiers in Nutrition.2023;[Epub]     CrossRef
• Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE−/− mice
  Lijun Zhu, Mingmei Xiao, Jigang Luo, Shijie Li, Wenting Liu, Jinchuan Wu, Zhuoyue Song
  International Journal of Biological Macromolecules.2023; 235: 123853.     CrossRef
• Improvement of Inflammation, Diabetes, and Obesity by Forest Product-Derived Polysaccharides through the Human Intestinal Microbiota
  Seong-woo MYEONG, Yong Ju LEE, Do Hyun KIM, Tae-Jong KIM
  Journal of the Korean Wood Science and Technology.2023; 51(5): 358.     CrossRef
• Recent developments in Salvia miltiorrhiza polysaccharides: Isolation, purification, structural characteristics and biological activities
  Lei Luo, Juan Xue, Zheng Shao, Zhang Zhou, Wenqian Tang, Jinxin Liu, Hongfei Hu, Fan Yang
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• In Vitro Probiotic Properties of Bifidobacterium animalis subsp. lactis SF and Its Alleviating Effect on Non-Alcoholic Fatty Liver Disease
  Huihui Lv, Feiyue Tao, Lingling Peng, Shufang Chen, Zhongyue Ren, Jiahui Chen, Bo Yu, Hua Wei, Cuixiang Wan
  Nutrients.2023; 15(6): 1355.     CrossRef
• Ginsenoside Rg1 Ameliorates Pancreatic Injuries via the AMPK/mTOR Pathway in vivo and in vitro
  Jin Chen, Guoping Zhu, Wenbo Xiao, Xiaosong Huang, Kewu Wang, Yi Zong
  Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 779.     CrossRef
• Managing metabolic diseases: The roles and therapeutic prospects of herb-derived polysaccharides
  Xinmei Xu, Lijie Wang, Kun Zhang, Yi Zhang, Gang Fan
  Biomedicine & Pharmacotherapy.2023; 161: 114538.     CrossRef
• Probio-X Relieves Symptoms of Hyperlipidemia by Regulating Patients’ Gut Microbiome, Blood Lipid Metabolism, and Lifestyle Habits
  Huan Wang, Cuicui Ma, Yan Li, Lei Zhang, lima A, Chengcong Yang, Feiyan Zhao, Haifeng Han, Dongyang Shang, Fan Yang, Yuying Zhang, Heping Zhang, Zhihong Sun, Ruifang Guo, Yuan Pin Hung
  Microbiology Spectrum.2023;[Epub]     CrossRef
• Sea cucumber sulfated polysaccharides and Lactobacillus gasseri synergistically ameliorate the overweight induced by altered gut microbiota in mice
  Zhengqi Liu, Chunqing Ai, Xinping Lin, Xiaoming Guo, Shuang Song, Beiwei Zhu
  Food & Function.2023; 14(9): 4106.     CrossRef
• Supplementation of Lactobacillus plantarum ATCC14917 mitigates non-alcoholic fatty liver disease in high-fat-diet-fed rats
  Xingjian Wen, Hejing Liu, Xiaoling Luo, Li Lui, Jiuyu Fan, Yajing Xing, Jia Wang, Xingfang Qiao, Na Li, Guixue Wang
  Frontiers in Microbiology.2023;[Epub]     CrossRef
• Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
  Ling Ye, Shicheng Fan, Pengfei Zhao, Chenghua Wu, Menghua Liu, Shuang Hu, Peng Wang, Hongyu Wang, Huichang Bi
  Acta Pharmaceutica Sinica B.2023; 13(9): 3598.     CrossRef
• α‐Lactalbumin Peptide Asp‐Gln‐Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids‐Treated HepG2 Cells and High‐Fat Diet‐Induced NAFLD Mice by Activating the PPARα Pathway
  Haoran Chen, Yanfeng Ma, Xiaofen Qi, Jianjun Tian, Ying Ma, Tianjiao Niu
  Molecular Nutrition & Food Research.2023;[Epub]     CrossRef
• Lonicerae flos polysaccharides improve nonalcoholic fatty liver disease by activating the adenosine 5′‐monophosphate‐activated protein kinase pathway and reshaping gut microbiota
  Chao Han, Zongshuo Li, Ruiying Liu, Zihan Zhao, Yu Wang, Xuli Zuo, Yushi Zhang, Zeyu Geng, Houyu Huang, Xiuzhen Pan, Weidong Li
  Journal of the Science of Food and Agriculture.2023; 103(15): 7721.     CrossRef
• Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
  Qin Guo, Yun Li, Xin Dai, Bangmao Wang, Jie Zhang, Hailong Cao
  Nutrients.2023; 15(17): 3722.     CrossRef
• Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease
  Alejandra Mijangos-Trejo, Natalia Nuño-Lambarri, Varenka Barbero-Becerra, Misael Uribe-Esquivel, Paulina Vidal-Cevallos, Norberto Chávez-Tapia
  International Journal of Molecular Sciences.2023; 24(19): 14918.     CrossRef
• Repair Effect and Mechanism of Electrospinning Nanocomposite Material with Gelatin-Bletilla Striata Gum/Salvia Miltiorrhiza on Orthopedic Refractory Wounds
  Geliang Hu, Ming Deng, Yonggang Ma, Jianghua Ming
  Journal of Biomedical Nanotechnology.2023; 19(10): 1783.     CrossRef
• Characterisation and skin protection activities of polysaccharides from Schnabelia terniflora
  Ying Zhao, Yixian Liu, Huoxiang Zhou, Wei Guo, Weidong Wang, Huiping Chen
  Natural Product Research.2023; : 1.     CrossRef
• Non-alcoholic fatty liver disease risk prediction model and health management strategies for older Chinese adults: a cross-sectional study
  Hong Pan, Baocheng Liu, Xin Luo, Xinxin Shen, Jijia Sun, An Zhang
  Lipids in Health and Disease.2023;[Epub]     CrossRef
• Modulatory effects of polysaccharides from plants, marine algae and edible mushrooms on gut microbiota and related health benefits: A review
  Henan Zhang, Fuchun Jiang, Jinsong Zhang, Wenhan Wang, Lin Li, Jingkun Yan
  International Journal of Biological Macromolecules.2022; 204: 169.     CrossRef
• Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification
  Guoyan Jiang, Chunhong Sun, Xiaodong Wang, Jie Mei, Chen Li, Honghong Zhan, Yixuan Liao, Yongjun Zhu, Jingxin Mao
  Bioengineered.2022; 13(3): 5216.     CrossRef
• Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
  Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do
  Biomedicines.2022; 10(3): 550.     CrossRef
• Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis
  Yu Hu, Zhen Ye, Yingqi She, Linzhen Li, Mingquan Wu, Kaihua Qin, Yuzheng Li, Haiqing He, Zhipeng Hu, Maoyi Yang, Fating Lu, Qiaobo Ye
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review
  Faezah Sabirin, Siong Meng Lim, Chin Fen Neoh, Kalavathy Ramasamy
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets
  Jie Liu, Yun Shi, Daiyin Peng, Lei Wang, Nianjun Yu, Guokai Wang, Weidong Chen
  Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
• The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases
  Yijing Ren, Siyue Li, Zixuan Song, Qiuping Luo, Yingying Zhang, Hao Wang
  Nutrients.2022; 14(11): 2303.     CrossRef
• Astaxanthin Alleviates Nonalcoholic Fatty Liver Disease by Regulating the Intestinal Flora and Targeting the AMPK/Nrf2 Signal Axis
  Yuhang Li, Juxiong Liu, Bojian Ye, Yueyao Cui, Ruiqi Geng, Shu Liu, Yufei Zhang, Wenjin Guo, Shoupeng Fu
  Journal of Agricultural and Food Chemistry.2022; 70(34): 10620.     CrossRef
• Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
  Mingmei Shao, Yifei Lu, Hongjiao Xiang, Junmin Wang, Guang Ji, Tao Wu
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• The chemistry and efficacy benefits of polysaccharides from Atractylodes macrocephala Koidz
  Congying Liu, Shengguang Wang, Zedong Xiang, Tong Xu, Mengyuan He, Qing Xue, Huaying Song, Peng Gao, Zhufeng Cong
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies
  Min-Han Chi, Jung Chao, Chien-Yu Ko, Shyh-Shyun Huang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Three water soluble polysaccharides with anti-inflammatory activities from Selaginella uncinata (Desv.) Spring
  Haochen Hui, Meng Gao, Xuerong Zhao, Lianhong Yin, Lina Xu, Lili Li, Jinyong Peng
  International Journal of Biological Macromolecules.2022; 222: 1983.     CrossRef
• Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut–Liver Axis
  Xiang Chen, Menghan Liu, Jun Tang, Ning Wang, Yibin Feng, Haotian Ma
  International Journal of Molecular Sciences.2022; 23(19): 11710.     CrossRef
• Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet
  Sai Wang, Xin-Yu Li, Hong-Fang Ji, Liang Shen
  Life Sciences.2022; 310: 121110.     CrossRef
• Structural Alteration of Gut Microbiota During the Amelioration of Chronic Psychological Stress-Aggravated Diabetes-Associated Cognitive Decline by a Traditional Chinese Herbal Formula, ZiBu PiYin Recipe
  Wen Zhou, Libin Zhan, Huiying Xu, Lijing Zhang
  Journal of Alzheimer's Disease.2022; 90(4): 1465.     CrossRef
• Bacillus amyloliquefaciens SC06 in the diet improves egg quality of hens by altering intestinal microbiota and the effect is diminished by antimicrobial peptide
  Shujie Xu, Fei Wang, Peng Zou, Xiang Li, Qian Jin, Qi Wang, Baikui Wang, Yuanhao Zhou, Li Tang, Dongyou Yu, Weifen Li
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• Effect of stigma maydis polysaccharide on the gut microbiota and transcriptome of VPA induced autism model rats
  Xiaolei Yang, Jiyuan Li, Yang Zhou, Ning Zhang, Jicheng Liu
  Frontiers in Microbiology.2022;[Epub]     CrossRef
• Salvia miltiorrhiza extract may exert an anti-obesity effect in rats with high-fat diet-induced obesity by modulating gut microbiome and lipid metabolism
  Zi-Li Ai, Xian Zhang, Wei Ge, You-Bao Zhong, Hai-Yan Wang, Zheng-Yun Zuo, Duan-Yong Liu
  World Journal of Gastroenterology.2022; 28(43): 6131.     CrossRef
• Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice
  Fang Xie, Hang-fei Xu, Jing Zhang, Xiao-ni Liu, Bu-xin Kou, Meng-yin Cai, Jing Wu, Jin-ling Dong, Qing-hua Meng, Yi Wang, Dexi Chen, Yang Zhang
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Structural elucidation and anti-nonalcoholic fatty liver disease activity of Polygonatum cyrtonema Hua polysaccharide
  Wei Liu, Taili Shao, Lei Tian, Zhengrui Ren, Lan Gao, Zhiyan Tang, Zheng Fang, Pingchuan Yuan, Chunyan Liu, Jikun Li, Guodong Wang, Jun Han
  Food & Function.2022; 13(24): 12883.     CrossRef
• The protective effects of sulforaphane on high-fat diet-induced metabolic associated fatty liver disease in mice via mediating the FXR/LXRα pathway
  Shaotong Ma, Xinyi Pang, Shuhua Tian, Jing Sun, Qiaobin Hu, Xiangfei Li, Yingjian Lu
  Food & Function.2022; 13(24): 12966.     CrossRef
• Gut Microbiota is A Crucial Bridge Mediating the Pharmacological Effect of Labiatae Traditional Chinese Medicine
  Yanan Yang, Fang Zhang, Jiaqi Yu, Chongming Wu
  Diseases and Research.2022; 2(1): 13.     CrossRef
• Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation
  Tingting Sang, Chengjie Guo, Dandan Guo, Jianjun Wu, Yujie Wang, Ying Wang, Jiajun Chen, Chaojie Chen, Kaikai Wu, Kun Na, Kang Li, Liu Fang, Cuiling Guo, Xingya Wang
  Carbohydrate Polymers.2021; 256: 117594.     CrossRef
• Annual review of LSD1/KDM1A inhibitors in 2020
  Dong-Jun Fu, Jun Li, Bin Yu
  European Journal of Medicinal Chemistry.2021; 214: 113254.     CrossRef
• Diet-Regulating Microbiota and Host Immune System in Liver Disease
  Jung A Eom, Goo Hyun Kwon, Na Yeon Kim, Eun Ju Park, Sung Min Won, Jin Ju Jeong, Ganesan Raja, Haripriya Gupta, Yoseph Asmelash Gebru, Satyapriya Sharma, Ye Rin Choi, Hyeong Seop Kim, Sang Jun Yoon, Ji Ye Hyun, Min Kyo Jeong, Hee Jin Park, Byeong Hyun Min
  International Journal of Molecular Sciences.2021; 22(12): 6326.     CrossRef
• Lactobacillus johnsonii BS15 combined with abdominal massage on intestinal permeability in rats with nonalcoholic fatty liver and cell biofilm repair
  Wei Zhang, Huanan Li, Na Zhao, Xiongfei Luo, Siwen Liu, an Bao, Yingying Chen, Haiteng Wang, Junshi Wang, Jingui Wang
  Bioengineered.2021; 12(1): 6354.     CrossRef
• Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review
  Hang-Yu Li, Dan-Dan Zhou, Ren-You Gan, Si-Yu Huang, Cai-Ning Zhao, Ao Shang, Xiao-Yu Xu, Hua-Bin Li
  Nutrients.2021; 13(9): 3211.     CrossRef
• Correlation Analysis of Huayu Tongmai Decoction Intervention and Prognosis Indexes of Patients with Carotid Atherosclerosis
  Guangqing Cheng, Xiaoni Yan, Fengmeng Wang, Chao Chen, Muhammad Wasim Khan
  Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1.     CrossRef
• Targeting the gut microbiota by Asian and Western dietary constituents: a new avenue for diabetes
  Abdul Rahman Conteh, Ruixue Huang
  Toxicology Research.2020; 9(4): 569.     CrossRef
• MiR-455 targeting SOCS3 improve liver lipid disorders in diabetic mice
  Shu Fang, Jie Feng, Hongbin Zhang, Ping Li, Yudan Zhang, Yanmei Zeng, Yingying Cai, Xiaochun Lin, Yaoming Xue, Meiping Guan
  Adipocyte.2020; 9(1): 179.     CrossRef
• Chinese Medicinal Herbs Targeting the Gut–Liver Axis and Adipose Tissue–Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science
  Shuwei Zhang, Yui-Tung Wong, Ka-Yu Tang, Hiu-Yee Kwan, Tao Su
  Frontiers in Endocrinology.2020;[Epub]     CrossRef
• Probiyotiklerin Kolon Mikrobiyotasına Etkileri: Güncel Çalışmalar
  Çağlar GÖKIRMAKLI, Zeynep SEYDİM
  Journal of Biotechnology and Strategic Health Research.2020; 4(3): 212.     CrossRef

About this article

Wang W, Xu AL, Li ZC, Li Y, Xu SF, Sang HC, Zhi F. Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice. Diabetes Metab J. 2020;44(2):336-348.

Received: Mar 04, 2019; Accepted: May 09, 2019

DOI: https://doi.org/10.4093/dmj.2019.0042.

Download citation ↓